Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

As an innovative sublingual tablet, this product stands out for its effectiveness and ease of use. By harnessing the power of semaglutide, GetSimpli provides a natural approach to weight loss that ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

“I’m making money to afford semagultide,” Rice, 42, who works three jobs to afford the expensive injectables, explained to her over 14,000 TikTok fans . Classified as a GLP-1, appetite-suppressing ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...